Argatroban

Antihirudin antibodies develop in 40% to 74% of patients receiving lepirudin after 4 days or more of treatment. Of note, fatal anaphylaxis has been described with lepirudin, particularly in patients who are treated again within 3 months of a previous exposure to this agent. In contrast, argatroban does not appear to be immunogenic. Argatroban is […]